查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566974

细胞毒性药物市场：按药物类型、应用、给药途径、分销管道分类：2024-2033年全球机会分析和产业预测

Cytotoxic Drug Market By Drug Type , By Application By Route of Administration By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 245 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年细胞毒性药物市值为158亿美元，预计2024年至2033年复合年增长率为2.1%，到2033年达到195亿美元。

细胞毒性药物是透过直接作用于 DNA 或抑制蛋白质生物合成来抑制癌细胞生长的化疗药物。然而，它们的使用通常会带来严重的副作用，因为它们也会作用于经常分裂的健康细胞，例如骨髓、胃肠道和毛囊中的细胞。儘管有这些挑战，细胞毒性药物在各种癌症的治疗中仍然至关重要，有助于提高存活率并改善疾病管理。

全球细胞毒性药物市场的成长主要是由癌症盛行率的惊人成长所推动的。据世界卫生组织 (WHO) 称，癌症是第一大死因，预计 2020 年将有约 1,000 万人死亡。此外，老年人口的快速增加也对全球市场的成长做出了重大贡献。这是因为老年人更容易罹患癌症，导致对癌症治疗的需求增加。此外，提高对癌症早期检测和治疗的认识是市场的关键驱动力。美国癌症协会强调，早期诊断的癌症患者五年存活率为90%，而晚期诊断的患者五年存活率为20%；我们强调细胞毒性药物在发现和后续使用中的重要性；治疗。人们越来越注重开发针对个别患者遗传特征的标靶细胞毒性疗法，以提高治疗效果并最大限度地减少副作用，这进一步推动了市场成长。此外，口服细胞毒性药物因其方便性和易于给药而受到高度欢迎，能够提高患者的依从性和生活质量，从而促进市场成长。然而，与细胞毒性药物相关的副作用，如噁心、脱髮和骨髓抑制，限制了它们的使用，从而阻碍了全球市场的成长。此外，人们对更有效治疗方法的认识不断增强，例如标靶治疗、免疫疗法和其他创新的癌症治疗方法，很可能会减少对传统细胞毒性药物的需求，导致市场这成为阻碍因素。相反，药物配方和药物输送系统的创新，以提高细胞毒性药物的功效和安全性，预计将为预测期内全球市场的成长提供有利的机会。例如，最近的研究表明，细胞毒性药物的新配方（例如脂质体阿霉素）可以减少副作用并改善患者的治疗效果。临床试验表明，这些先进的製剂可以将肿瘤部位的药物传递增强 30-40%。

全球细胞毒性药物市场按药物类型、应用、给药途径、分销管道和区域细分。依药物类型分为烷化剂、抗肿瘤抗生素、抗代谢药、植物生物碱等。依用途分为乳癌、摄护腺癌、肺癌、胰臟癌等。依给药途径，药物分为口服药物和肠外药物。按分销管道划分，可分为医院药房、药局和零售药房以及线上提供者。从区域来看，分析包括北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按药物类型划分，抗代谢药物预计在 2033 年占据市场主导地位。

从应用来看，乳癌预计将在预测期内成为主要细分市场。

从给药途径来看，口服製剂预计在未来几年将呈现最高成长。

从分销管道来看，医院药房部门很可能在不久的将来引领全球细胞毒性药物市场。

按地区划分，北美是 2023 年细胞毒性药物市场的主要股东，预计在整个预测期内将保持主导地位。

该报告可以定制（需要单独的费用和时间表）。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章细胞毒性药物市场：依药物类型

  • 市场概况
  • 烷化剂
  • 抗肿瘤抗生素
  • 抗代谢药
  • 植物生物碱
  • 其他的

第五章细胞毒性药物市场：依应用分类

  • 市场概况
  • 乳癌
  • 摄护腺癌
  • 肺癌
  • 胰臟癌
  • 其他的

第六章 细胞毒性药物市场：依给药途径

  • 市场概况
  • 口服剂
  • 胃肠外的

第七章 临床有毒药品市场：依通路

  • 市场概况
  • 医院药房
  • 药局和零售药局
  • 线上提供者

第八章细胞毒性药物市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国细胞毒药物市场
    • 加拿大细胞毒性药物市场
    • 墨西哥细胞毒性药物市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国细胞毒药物市场
    • 法国细胞毒药物市场
    • 英国细胞毒药物市场
    • 义大利细胞毒药物市场
    • 西班牙细胞毒药物市场
    • 其他欧洲细胞毒性药物市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本细胞毒药物市场
    • 中国细胞毒药物市场
    • 印度细胞毒性药物市场
    • 澳洲细胞毒药物市场
    • 韩国细胞毒药物市场
    • 其他亚太细胞毒性药物市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西细胞毒性药物市场
    • 沙乌地阿拉伯细胞毒性药物市场
    • 南非细胞毒性药物市场
    • 其他拉丁美洲/中东/非洲细胞毒性药物市场

第9章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第十章 公司简介

  • Baxter
  • Cipla Ltd
  • Eli Lilly And Company
  • Fresenius Kabi AG
  • Johnson And Johnson
  • Novartis AG
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
简介目录
Product Code: A324399

The cytotoxic drug market was valued at $15.8 billion in 2023, and is projected to reach $19.5 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.

Cytotoxic drugs are chemotherapeutic agents that inhibit the growth of cancer cells by acting directly on the DNA or interfering with the biosynthesis of proteins. However, because they also affect healthy cells that divide frequently, such as those in the bone marrow, digestive tract, and hair follicles, their use is often accompanied by significant side effects. Despite these challenges, cytotoxic drugs remain essential in the treatment of various cancers, contributing to improved survival rates and better management of the disease.

The growth of the global cytotoxic drug market is majorly driven by alarming increase prevalence of cancer. According to the World Health Organization, cancer is the leading cause of death, and accounted for approximately 10 million deaths in 2020, thus fueling the demand for effective chemotherapy treatments, including cytotoxic drugs. Moreover, surge in geriatric population significantly contributes toward the growth of the global market. This is attributed to the fact that aged individuals are highly susceptible to cancer, leading to higher demand for cancer treatments. Furthermore, rise in awareness about early detection and treatment of cancer acts as the key driving force of the market. The American Cancer Society highlights that the five-year survival rate for cancer patients diagnosed at an early stage is 90%, compared to 20% for those diagnosed at a later stage, thereby highlighting the importance of early detection and the consequent use of cytotoxic drugs in treatment. Rise in emphasis on developing targeted cytotoxic therapies tailored to individual patients' genetic profiles to improve treatment efficacy and minimize side effects is further propelling the market growth. In addition, oral cytotoxic drugs are gaining high traction due to their convenience and ease of administration, allowing for better patient compliance and quality of life, thus augmenting the market growth. However, adverse effects associated with cytotoxic drugs, such as nausea, hair loss, and bone marrow suppression, limit their use, which hampers the growth of the global market. In addition, rise in awareness about more effective therapies such as targeted therapies, immunotherapies, and other innovative cancer treatments potentially reduce the demand for traditional cytotoxic drugs, which acts as the key deterrent factor of the market. On the contrary, innovations in drug formulation and delivery systems to enhance the efficacy and safety of cytotoxic drugs are expected to offer lucrative opportunities for the growth of the global market during the forecast period. For instance, recent studies have shown that new formulations of cytotoxic drugs, such as liposomal doxorubicin, can reduce side effects and improve patient outcomes. Clinical trials have demonstrated that these advanced formulations can enhance drug delivery to tumor sites by 30-40%.

The global cytotoxic drug market is segmented into drug type, application, route of administration, distribution channel, and region. On the basis of the drug type, the market is segregated into alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. As per application, it is classified into breast cancer, prostate cancer, lung cancer, pancreatic cancer, and others. By route of administration, it is bifurcated into oral and parenteral. According to distribution channel, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By drug type, the antimetabolites segment is expected to dominate the market by 2033.

On the basis of application, breast cancer is anticipated to emerge as a leading segment during the forecast period.

Depending on route of administration, the oral segment is projected to exhibit the highest growth in the coming years.

As per distribution channel, the hospital pharmacies segment is likely to lead the lobal cytotoxic drug market in the near future.

Region wise, North America was the major shareholder in the cytotoxic drug market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global cytotoxic drug market include Baxter, Cipla Ltd, Eli Lilly and Company, Fresenius Kabi AG, Johnson & Johnson, Novartis AG, Viatris Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Type

  • Alkylating Agents
  • Antitumor Antibiotics
  • Antimetabolites
  • Plant Alkaloids
  • Others

By Application

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others

By Route Of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Baxter
    • Cipla Ltd
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • Johnson & Johnson
    • Novartis AG
    • Viatris Inc.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CYTOTOXIC DRUG MARKET, BY DRUG TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Type
  • 4.2. Alkylating Agents
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Antitumor Antibiotics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Antimetabolites
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Plant Alkaloids
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: CYTOTOXIC DRUG MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Breast Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Prostate Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Lung Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Pancreatic Cancer
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Others
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: CYTOTOXIC DRUG MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Route of Administration
  • 6.2. Oral
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Parenteral
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: CYTOTOXIC DRUG MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Distribution Channel
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Drug Stores And Retail Pharmacies
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Online Providers
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: CYTOTOXIC DRUG MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Drug Type
    • 8.2.3. Market Size and Forecast, By Application
    • 8.2.4. Market Size and Forecast, By Route of Administration
    • 8.2.5. Market Size and Forecast, By Distribution Channel
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Cytotoxic Drug Market
      • 8.2.7.1. Market Size and Forecast, By Drug Type
      • 8.2.7.2. Market Size and Forecast, By Application
      • 8.2.7.3. Market Size and Forecast, By Route of Administration
      • 8.2.7.4. Market Size and Forecast, By Distribution Channel
    • 8.2.8. Canada Cytotoxic Drug Market
      • 8.2.8.1. Market Size and Forecast, By Drug Type
      • 8.2.8.2. Market Size and Forecast, By Application
      • 8.2.8.3. Market Size and Forecast, By Route of Administration
      • 8.2.8.4. Market Size and Forecast, By Distribution Channel
    • 8.2.9. Mexico Cytotoxic Drug Market
      • 8.2.9.1. Market Size and Forecast, By Drug Type
      • 8.2.9.2. Market Size and Forecast, By Application
      • 8.2.9.3. Market Size and Forecast, By Route of Administration
      • 8.2.9.4. Market Size and Forecast, By Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Drug Type
    • 8.3.3. Market Size and Forecast, By Application
    • 8.3.4. Market Size and Forecast, By Route of Administration
    • 8.3.5. Market Size and Forecast, By Distribution Channel
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Cytotoxic Drug Market
      • 8.3.7.1. Market Size and Forecast, By Drug Type
      • 8.3.7.2. Market Size and Forecast, By Application
      • 8.3.7.3. Market Size and Forecast, By Route of Administration
      • 8.3.7.4. Market Size and Forecast, By Distribution Channel
    • 8.3.8. France Cytotoxic Drug Market
      • 8.3.8.1. Market Size and Forecast, By Drug Type
      • 8.3.8.2. Market Size and Forecast, By Application
      • 8.3.8.3. Market Size and Forecast, By Route of Administration
      • 8.3.8.4. Market Size and Forecast, By Distribution Channel
    • 8.3.9. UK Cytotoxic Drug Market
      • 8.3.9.1. Market Size and Forecast, By Drug Type
      • 8.3.9.2. Market Size and Forecast, By Application
      • 8.3.9.3. Market Size and Forecast, By Route of Administration
      • 8.3.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3.10. Italy Cytotoxic Drug Market
      • 8.3.10.1. Market Size and Forecast, By Drug Type
      • 8.3.10.2. Market Size and Forecast, By Application
      • 8.3.10.3. Market Size and Forecast, By Route of Administration
      • 8.3.10.4. Market Size and Forecast, By Distribution Channel
    • 8.3.11. Spain Cytotoxic Drug Market
      • 8.3.11.1. Market Size and Forecast, By Drug Type
      • 8.3.11.2. Market Size and Forecast, By Application
      • 8.3.11.3. Market Size and Forecast, By Route of Administration
      • 8.3.11.4. Market Size and Forecast, By Distribution Channel
    • 8.3.12. Rest of Europe Cytotoxic Drug Market
      • 8.3.12.1. Market Size and Forecast, By Drug Type
      • 8.3.12.2. Market Size and Forecast, By Application
      • 8.3.12.3. Market Size and Forecast, By Route of Administration
      • 8.3.12.4. Market Size and Forecast, By Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Drug Type
    • 8.4.3. Market Size and Forecast, By Application
    • 8.4.4. Market Size and Forecast, By Route of Administration
    • 8.4.5. Market Size and Forecast, By Distribution Channel
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Cytotoxic Drug Market
      • 8.4.7.1. Market Size and Forecast, By Drug Type
      • 8.4.7.2. Market Size and Forecast, By Application
      • 8.4.7.3. Market Size and Forecast, By Route of Administration
      • 8.4.7.4. Market Size and Forecast, By Distribution Channel
    • 8.4.8. China Cytotoxic Drug Market
      • 8.4.8.1. Market Size and Forecast, By Drug Type
      • 8.4.8.2. Market Size and Forecast, By Application
      • 8.4.8.3. Market Size and Forecast, By Route of Administration
      • 8.4.8.4. Market Size and Forecast, By Distribution Channel
    • 8.4.9. India Cytotoxic Drug Market
      • 8.4.9.1. Market Size and Forecast, By Drug Type
      • 8.4.9.2. Market Size and Forecast, By Application
      • 8.4.9.3. Market Size and Forecast, By Route of Administration
      • 8.4.9.4. Market Size and Forecast, By Distribution Channel
    • 8.4.10. Australia Cytotoxic Drug Market
      • 8.4.10.1. Market Size and Forecast, By Drug Type
      • 8.4.10.2. Market Size and Forecast, By Application
      • 8.4.10.3. Market Size and Forecast, By Route of Administration
      • 8.4.10.4. Market Size and Forecast, By Distribution Channel
    • 8.4.11. South Korea Cytotoxic Drug Market
      • 8.4.11.1. Market Size and Forecast, By Drug Type
      • 8.4.11.2. Market Size and Forecast, By Application
      • 8.4.11.3. Market Size and Forecast, By Route of Administration
      • 8.4.11.4. Market Size and Forecast, By Distribution Channel
    • 8.4.12. Rest of Asia-Pacific Cytotoxic Drug Market
      • 8.4.12.1. Market Size and Forecast, By Drug Type
      • 8.4.12.2. Market Size and Forecast, By Application
      • 8.4.12.3. Market Size and Forecast, By Route of Administration
      • 8.4.12.4. Market Size and Forecast, By Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Drug Type
    • 8.5.3. Market Size and Forecast, By Application
    • 8.5.4. Market Size and Forecast, By Route of Administration
    • 8.5.5. Market Size and Forecast, By Distribution Channel
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Cytotoxic Drug Market
      • 8.5.7.1. Market Size and Forecast, By Drug Type
      • 8.5.7.2. Market Size and Forecast, By Application
      • 8.5.7.3. Market Size and Forecast, By Route of Administration
      • 8.5.7.4. Market Size and Forecast, By Distribution Channel
    • 8.5.8. Saudi Arabia Cytotoxic Drug Market
      • 8.5.8.1. Market Size and Forecast, By Drug Type
      • 8.5.8.2. Market Size and Forecast, By Application
      • 8.5.8.3. Market Size and Forecast, By Route of Administration
      • 8.5.8.4. Market Size and Forecast, By Distribution Channel
    • 8.5.9. South Africa Cytotoxic Drug Market
      • 8.5.9.1. Market Size and Forecast, By Drug Type
      • 8.5.9.2. Market Size and Forecast, By Application
      • 8.5.9.3. Market Size and Forecast, By Route of Administration
      • 8.5.9.4. Market Size and Forecast, By Distribution Channel
    • 8.5.10. Rest of LAMEA Cytotoxic Drug Market
      • 8.5.10.1. Market Size and Forecast, By Drug Type
      • 8.5.10.2. Market Size and Forecast, By Application
      • 8.5.10.3. Market Size and Forecast, By Route of Administration
      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Baxter
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Cipla Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Eli Lilly And Company
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Fresenius Kabi AG
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Johnson And Johnson
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. Viatris Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Sun Pharmaceutical Industries Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments